Surgeons frequently encounter microvascular bleeding during complex spinal fusion procedures, but unexpected profuse hemorrhage presents a catastrophic intraoperative challenge. In rare instances, de novo immune thrombocytopenia can manifest abruptly during surgery in patients with completely normal baseline laboratory parameters. Recognizing this acute hematologic crisis early remains essential to prevent fatal perioperative complications, hemorrhagic shock, and permanent neurologic deficits. Clinicians must maintain a heightened index of suspicion when routine surgical hemostasis fails despite normal preoperative coagulation profiles.

Clinical Presentation and Initial Intraoperative Dilemma

Major lumbar spine surgeries, such as posterior lumbar interbody fusion (PLIF), inherently carry a moderate risk of blood loss due to the rich venous networks surrounding the epidural space and vertebral bodies. However, surgical teams typically control this bleeding using bipolar cautery, topical hemostatic agents, and careful dissection. In an exceptional clinical scenario, an 81-year-old female undergoing multi-level lumbar fusion developed diffuse, uncontrolled microvascular oozing midway through the interbody procedures. Preoperative laboratory testing had demonstrated completely normal platelet counts and standard coagulation assays.

Because the surgical field showed persistent diffuse oozing without isolated arterial disruption, the surgical team faced a severe diagnostic puzzle. Intraoperative coagulation parameters remained within baseline limits, yet hemorrhage escalated progressively. Despite conventional local interventions, extensive packing, and meticulous electrosurgery, bleeding persisted throughout the operation. Postoperative monitoring revealed a precipitous hematologic collapse, with the platelet count dropping dramatically to an alarming nadir of 1,000/µL by postoperative day one. Furthermore, emergency platelet transfusions yielded virtually no increment in circulating platelet levels, raising urgent concerns for rapid platelet destruction rather than simple surgical consumption.

Diagnostic Workup of De Novo Immune Thrombocytopenia

When sudden, life-threatening thrombocytopenia occurs perioperatively, clinicians must rapidly differentiate immune-mediated platelet destruction from other critical pathologies. The differential diagnosis includes heparin-induced thrombocytopenia, disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and drug-induced immune thrombocytopenia. In this patient, peripheral blood smears confirmed severe true isolated thrombocytopenia without schistocytes or microangiopathic hemolysis, effectively ruling out primary microangiopathies. Furthermore, normal fibrinogen levels, normal D-dimer trajectories, and intact prothrombin times excluded consumptive coagulopathy associated with systemic DIC.

Consequently, after thoroughly evaluating all potential pharmacological triggers and excluding secondary infectious or lymphoproliferative disorders, clinicians established a diagnosis of acute de novo immune thrombocytopenia. The patient subsequently exhibited widespread systemic bleeding signs, including diffuse petechiae, gross hematuria, and severe alveolar hemorrhage. This systemic involvement confirmed that the intraoperative bleeding represented the opening presentation of a widespread autoimmune assault rather than localized surgical vascular trauma. Therefore, early hematologic consultation and urgent repeat complete blood counts provide critical diagnostic clarity when encountering refractory intraoperative oozing.

Pathophysiology and Perioperative Platelet Dynamics

Primary immune thrombocytopenia develops when autoantibodies target platelet membrane glycoproteins, specifically glycoprotein IIb/IIIa or Ib/IX complexes. Macrophages within the reticuloendothelial system, predominantly in the spleen and liver, recognize these antibody-coated platelets via Fc gamma receptors and clear them rapidly from circulation. Additionally, autoreactive cytotoxic T lymphocytes directly suppress megakaryocytopoiesis within the bone marrow, leading to impaired compensatory platelet production.

Surgical trauma, systemic inflammation, and perioperative physiological stress can theoretically act as catalytic triggers for acute immune dysregulation in predisposed individuals. When acute de novo ITP develops during an invasive procedure, circulating platelets undergo accelerated destruction within minutes to hours. This explains why conventional donor platelet transfusions fail to elevate platelet counts effectively; the circulating antiplatelet autoantibodies destroy transfused donor platelets just as rapidly as endogenous cells. Understanding this destructive pathophysiology is essential for surgical and anesthetic teams. Relying solely on platelet transfusions without concurrent immunosuppressive and thrombopoietic therapies delays definitive patient recovery.

Targeted Management Strategies and Thrombopoietin Agonists

Standard first-line therapy for acute immune thrombocytopenia centers on high-dose corticosteroids, such as intravenous dexamethasone or methylprednisolone, alongside high-dose intravenous immunoglobulin (IVIG). These agents rapidly reduce antibody-mediated destruction by blocking Fc receptors on reticuloendothelial macrophages and dampening autoantibody synthesis. However, some patients exhibit refractory disease where first-line immunosuppression alone fails to achieve hemostatic platelet levels.

In this clinical case, neither high-dose IVIG nor pulse corticosteroids induced adequate platelet recovery, leaving the patient at high risk for fatal central nervous system or pulmonary hemorrhage. Clinicians promptly escalated treatment by introducing a thrombopoietin receptor agonist (TPO-RA). These second-line agents, such as romiplostim or eltrombopag, directly stimulate the thrombopoietin receptor on bone marrow megakaryocytes, markedly increasing viable platelet production. Following TPO-RA administration, the patient achieved robust hematologic recovery with complete cessation of systemic bleeding manifestations. Long-term follow-up at one year demonstrated sustained normal platelet counts without disease recurrence, confirming that early second-line intervention can successfully resolve refractory acute episodes.

Multidisciplinary Protocols for Unexplained Surgical Bleeding

Managing sudden, massive intraoperative bleeding requires seamless communication and coordinated execution among spine surgeons, anesthesiologists, hematologists, and critical care specialists. When surgical teams observe diffuse microvascular bleeding that defies conventional hemostasis, they must immediately obtain emergency arterial blood gases, viscoelastic testing (such as TEG or ROTEM), and urgent automated complete blood counts. Identifying an isolated drop in platelets intraoperatively redirects the clinical strategy from futile surgical exploration toward immediate hematologic rescue.

Moreover, anesthesia teams must maintain normothermia, optimize acid-base balance, and avoid massive hemodilution, which exacerbates underlying coagulopathies. If surgeons suspect acute immune thrombocytopenia, they should consult a hematologist stat while initiating empiric first-line immunosuppression. Concurrently, clinicians should consider early escalation to thrombopoietin receptor agonists if platelet increments remain refractory. Establishing clear institutional pathways for unexplained intraoperative oozing ensures that operating room teams rapidly identify rare autoimmune hematologic crises and implement life-saving targeted therapies without delay.

Frequently Asked Questions

How quickly can de novo immune thrombocytopenia manifest during surgery?

De novo immune thrombocytopenia can develop precipitously within several hours of surgical incision. Although patients typically present with normal preoperative platelet counts, acute autoantibody-mediated destruction accelerates platelet clearance rapidly. Consequently, surgeons may observe diffuse microvascular oozing during the procedure, followed by severe thrombocytopenia on postoperative day one. Urgent intraoperative and postoperative platelet count evaluations remain vital for prompt detection and timely management.

Why do platelet transfusions often fail in acute immune thrombocytopenia?

Platelet transfusions generally show poor efficacy in acute immune thrombocytopenia because circulating autoantibodies target both endogenous and transfused donor platelets. The reticuloendothelial system rapidly destroys the transfused platelets via Fc receptor-mediated phagocytosis within minutes. Therefore, transfusions alone cannot sustain hemostatic platelet levels. Clinicians must simultaneously administer intravenous immunoglobulins, high-dose corticosteroids, or thrombopoietin receptor agonists to arrest antibody clearance and stimulate bone marrow production.

When should clinicians initiate thrombopoietin receptor agonists for refractory cases?

Clinicians should initiate thrombopoietin receptor agonists when acute immune thrombocytopenia fails to respond adequately to first-line therapies, including intravenous immunoglobulin and high-dose corticosteroids. In patients with ongoing critical bleeding or profound refractory thrombocytopenia below 10,000 to 20,000/µL, second-line thrombopoietin agonists like eltrombopag or romiplostim stimulate megakaryocytopoiesis. This targeted approach reliably drives rapid platelet production and achieves lasting hemostatic stabilization.

Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Healthcare professionals should rely on their clinical judgment and verify details independently. Refer to the latest local and national guidelines for clinical practice.

References

1. Mizukoshi R et al. Severe intraoperative bleeding as the initial manifestation of de novo immune thrombocytopenia during lumbar spinal fusion: a case report. Eur Spine J. 2026 Aug 23. doi: 10.1007/s00586-026-10294-8. PMID: 42633603.
2. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
3. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3787.
4. Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016;128(12):1547-1554.